AtriCure announced completion of enrollment for the LeAAPS trial evaluating its AtriClip left atrial appendage (LAA) exclusion system to prevent ischemic stroke and systemic arterial embolism in cardiac surgery patients without atrial fibrillation.
Started in January 2023, LeAAPS enrolled 6,500 patients across 137 global centers and will include five years of follow-up to assess long-term outcomes. The trial aims to support expanded stroke prevention indications and inform treatment guidelines.
AtriCure’s CEO Michael Carrel highlighted strong investigator engagement and the potential to expand market leadership with AtriClip, the world’s most widely used LAA management device.
Follow MEDWIRE.AI for cardiovascular innovation updates.
